Publications by authors named "Purav Bhatt"
Article Synopsis
- - The ASCEND-NHQ trial investigated the effectiveness of daprodustat in increasing hemoglobin levels and improving fatigue in adults with chronic kidney disease (CKD) stages 3-5, comparing it to a placebo over 28 weeks.
- - Results showed that participants taking daprodustat experienced a significant mean change in hemoglobin (1.58 g/dl) compared to the placebo group (0.19 g/dl), with 77% of daprodustat users achieving a 1 g/dl increase.
- - Additionally, the SF-36 Vitality score (which measures fatigue) improved more for those on daprodustat (7.3 points) than those on placebo (1.
Tolvaptan is an arginine vasopressin (AVP) antagonist that acts to increase excretion of free water (aquaresis) in patients without introducing electrolyte abnormalities or worsening renal function. It works via blockade of vasopressin-2 receptors at the renal collecting duct. Since the approval of tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia in 2009, new studies have been reported to better characterize its pharmacokinetic and pharmacodynamic profile of tolvaptan.
View Article and Find Full Text PDF